Cargando…

Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza

BACKGROUND: Vaccination against seasonal influenza strains is recommended for “high risk” patient groups such as infants, elderly and those with respiratory or circulatory diseases. However, efficacy of the trivalent influenza vaccine (TIV) is poor in many cases and in the event of an influenza pand...

Descripción completa

Detalles Bibliográficos
Autores principales: Heath, M. D, Swan, N. J., Marriott, A. C., Silman, N. J., Hallis, B., Prevosto, C., Gooch, K. E., Skinner, M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369220/
https://www.ncbi.nlm.nih.gov/pubmed/28347293
http://dx.doi.org/10.1186/s12879-017-2329-5
_version_ 1782518089886203904
author Heath, M. D
Swan, N. J.
Marriott, A. C.
Silman, N. J.
Hallis, B.
Prevosto, C.
Gooch, K. E.
Skinner, M. A.
author_facet Heath, M. D
Swan, N. J.
Marriott, A. C.
Silman, N. J.
Hallis, B.
Prevosto, C.
Gooch, K. E.
Skinner, M. A.
author_sort Heath, M. D
collection PubMed
description BACKGROUND: Vaccination against seasonal influenza strains is recommended for “high risk” patient groups such as infants, elderly and those with respiratory or circulatory diseases. However, efficacy of the trivalent influenza vaccine (TIV) is poor in many cases and in the event of an influenza pandemic, mono-valent vaccines have been rapidly developed and deployed. One of the main issues with use of vaccine in pandemic situations is the lack of a suitable quantity of vaccine early enough during the pandemic to exert a major influence on the transmission of virus and disease outcome. One approach is to use a dose-sparing regimen which inevitably involves enhancing the efficacy using adjuvants. METHODS: In this study we compare the use of a novel microcrystalline tyrosine (MCT) adjuvant, which is currently used in a niche area of allergy immunotherapy, for its ability to enhance the efficacy of a seasonal TIV preparation. The efficacy of the MCT adjuvant formulation was compared to alum adjuvanted TIV and to TIV administered without adjuvant using a ferret challenge model to determine vaccine efficacy. RESULTS: The MCT was found to possess high protein-binding capacity. In the two groups where TIV was formulated with adjuvant, the immune response was found to be higher (as determined by HAI titre) than vaccine administered without adjuvant and especially so after challenge with a live influenza virus. Vaccinated animals exhibited lower viral loads (as determined using RT-PCR) than control animals where no vaccine was administered. CONCLUSIONS: The attributes of each adjuvant in stimulating single-dose protection against a poorly immunogenic vaccine was demonstrated. The properties of MCT that lead to the reported effectiveness warrants further exploration in this and other vaccine targets - particularly where appropriate immunogenic, biodegradable and stable alternative adjuvants are sought. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2329-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5369220
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53692202017-03-30 Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza Heath, M. D Swan, N. J. Marriott, A. C. Silman, N. J. Hallis, B. Prevosto, C. Gooch, K. E. Skinner, M. A. BMC Infect Dis Research Article BACKGROUND: Vaccination against seasonal influenza strains is recommended for “high risk” patient groups such as infants, elderly and those with respiratory or circulatory diseases. However, efficacy of the trivalent influenza vaccine (TIV) is poor in many cases and in the event of an influenza pandemic, mono-valent vaccines have been rapidly developed and deployed. One of the main issues with use of vaccine in pandemic situations is the lack of a suitable quantity of vaccine early enough during the pandemic to exert a major influence on the transmission of virus and disease outcome. One approach is to use a dose-sparing regimen which inevitably involves enhancing the efficacy using adjuvants. METHODS: In this study we compare the use of a novel microcrystalline tyrosine (MCT) adjuvant, which is currently used in a niche area of allergy immunotherapy, for its ability to enhance the efficacy of a seasonal TIV preparation. The efficacy of the MCT adjuvant formulation was compared to alum adjuvanted TIV and to TIV administered without adjuvant using a ferret challenge model to determine vaccine efficacy. RESULTS: The MCT was found to possess high protein-binding capacity. In the two groups where TIV was formulated with adjuvant, the immune response was found to be higher (as determined by HAI titre) than vaccine administered without adjuvant and especially so after challenge with a live influenza virus. Vaccinated animals exhibited lower viral loads (as determined using RT-PCR) than control animals where no vaccine was administered. CONCLUSIONS: The attributes of each adjuvant in stimulating single-dose protection against a poorly immunogenic vaccine was demonstrated. The properties of MCT that lead to the reported effectiveness warrants further exploration in this and other vaccine targets - particularly where appropriate immunogenic, biodegradable and stable alternative adjuvants are sought. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2329-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-27 /pmc/articles/PMC5369220/ /pubmed/28347293 http://dx.doi.org/10.1186/s12879-017-2329-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Heath, M. D
Swan, N. J.
Marriott, A. C.
Silman, N. J.
Hallis, B.
Prevosto, C.
Gooch, K. E.
Skinner, M. A.
Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
title Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
title_full Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
title_fullStr Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
title_full_unstemmed Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
title_short Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
title_sort comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369220/
https://www.ncbi.nlm.nih.gov/pubmed/28347293
http://dx.doi.org/10.1186/s12879-017-2329-5
work_keys_str_mv AT heathmd comparisonofanovelmicrocrystallinetyrosineadjuvantwithaluminiumhydroxideforenhancingvaccinationagainstseasonalinfluenza
AT swannj comparisonofanovelmicrocrystallinetyrosineadjuvantwithaluminiumhydroxideforenhancingvaccinationagainstseasonalinfluenza
AT marriottac comparisonofanovelmicrocrystallinetyrosineadjuvantwithaluminiumhydroxideforenhancingvaccinationagainstseasonalinfluenza
AT silmannj comparisonofanovelmicrocrystallinetyrosineadjuvantwithaluminiumhydroxideforenhancingvaccinationagainstseasonalinfluenza
AT hallisb comparisonofanovelmicrocrystallinetyrosineadjuvantwithaluminiumhydroxideforenhancingvaccinationagainstseasonalinfluenza
AT prevostoc comparisonofanovelmicrocrystallinetyrosineadjuvantwithaluminiumhydroxideforenhancingvaccinationagainstseasonalinfluenza
AT goochke comparisonofanovelmicrocrystallinetyrosineadjuvantwithaluminiumhydroxideforenhancingvaccinationagainstseasonalinfluenza
AT skinnerma comparisonofanovelmicrocrystallinetyrosineadjuvantwithaluminiumhydroxideforenhancingvaccinationagainstseasonalinfluenza